Skip to content
Screener

Harrow HROW Financing Cash Flow

Financing Cash Flow at other companies

AbbVie logo
AbbVieABBV
$919M+173%
Eton Pharmaceuticals, Inc. logo
Eton Pharmaceuticals, Inc.ETON
$1.39M+253%
Bausch + Lomb logo
Bausch + LombBLCO
$34M-62.2%
Ocular Therapeutix logo
Ocular TherapeutixOCUL
$294K-93.0%
Opko Health logo
Opko HealthOPK
-$13.03M+83.6%
Bausch Health Companies logo
Bausch Health CompaniesBHC
-$100M+31.5%

Other financials

Income statement

See full
Revenue$44.2M-7.6%
Gross profit$27.0M-16.3%
Operating income-$22.1M-96.6%
Net income-$27.6M-55.2%
EPS (diluted)-$0.74-48.0%

Balance sheet

See full
Cash & equivalents$94.6M+41.8%
Total debt$308.6M-32.9%
Total equity$28.7M-49.1%
Total assets$419.5M+15.2%

Cash flow

See full
Operating cash flow-$9.0M-146%
CapEx$194.0K+14.1%
Free cash flow-$9.2M-147%

Valuation

See full
Market cap$1.49B+22.8%
Enterprise value$1.7B+5.6%
P/S5.5×+0.2×

Profitability

See full
Gross margin74.1%-0.4pp
Operating margin7.3%+5.2pp
Net margin-19.8%+18.0pp
FCF margin5.7%+5.0pp

Returns & leverage

See full
Return on equity-50%+17.5pp
Debt / equity10.7×+2.6×
Current ratio2.5×+1.6×

Where this comes from

Reported directly by Harrow in its filing.

Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInFinancingActivities.

The source filing: Harrow’s 10-Q, filed May 11, 2026.

Filed
May 11, 2026, 4:31 PM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0001493152-26-022254
Line item2026 / For the Three Months Ended March 31,2025 / For the Three Months Ended March 31,
Net proceeds from 8.625% notes payable, net of commissions49,000,000-
Payment of debt issuance costs(113,000)-
Proceeds from exercise of stock options25,00023,000
NET CASH PROVIDED BY FINANCING ACTIVITIES48,912,00023,000
NET CHANGE IN CASH AND CASH EQUIVALENTS21,717,00019,479,000
CASH AND CASH EQUIVALENTS, beginning of period72,927,00047,247,000
CASH, CASH EQUIVALENTS, end of period$94,644,000$66,726,000
SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION:

Item 1. Financial Statements (unaudited) Item

FAQ

What is Harrow's financing cash flow?
Harrow (HROW) reported financing cash flow of $48.91M in Q1 2026.
How has Harrow's financing cash flow changed year-over-year?
Harrow's financing cash flow increased by 212560.9% year-over-year, from $23K to $48.91M.
What is the long-term trend for Harrow's financing cash flow?
Over 3 years (2021 to 2024), Harrow's financing cash flow has grown at a -17.9% compound annual growth rate (CAGR), from $51.47M to $28.53M.
What does financing cash flow mean?
Total net cash provided by or used in financing activities — debt issuance/repayment, equity transactions, and dividend payments.

Ask your AI about Harrow's financing cash flow.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude